Andrew D.J. Pearson

18.6k citations

224 papers · 11.4k indexed · 3 hit papers · h-index 54

Impact in

Neurology top 0.05%
- Neuroblastoma Research and Treatments
Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism

Papers in

Neurology 110
- Neuroblastoma Research and Treatments 109
Cancer Research 59
- Cancer, Hypoxia, and Metabolism 49

Co-authors: Susan L. Cohn Katherine K. Matthay Wendy B. London Peter F. Ambros Tom Monclair David Machin Thorsten Simon Alan V. Boddy
Journals: Journal of Clinical Oncology (41 papers)European Journal of Cancer (17 papers)Pediatric Blood & Cancer (16 papers)British Journal of Cancer (11 papers)Clinical Cancer Research (10 papers)
Partner nations: United Kingdom France United States

In The Last Decade

Andrew D.J. Pearson

218 papers receiving 11.2k citations

Hit Papers

align trajectories log scale

Advances in Risk Classification and Treatment Strategies for Neuroblastoma 2015 · 611 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2015 Journal of Clinical Oncology
2008 Journal of Clinical Oncology
2008 Journal of Clinical Oncology

Peers

Countries citing papers authored by Andrew D.J. Pearson

Since Specialization

Citations

This map shows the geographic impact of Andrew D.J. Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D.J. Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D.J. Pearson more than expected).

Fields of papers citing papers by Andrew D.J. Pearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D.J. Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D.J. Pearson. The network helps show where Andrew D.J. Pearson may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew D.J. Pearson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew D.J. Pearson Line = papers co-authored together Andrew D.J. Pearson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus Clinical Pharmacology & Therapeutics ·Teresa de Rojas, Davy Chiodin, Andrew D.J. Pearson, Delphine Heenen, Peter C. Adamson, Hubert Caron, Gilles Vassal	2023	0
2	Noninvasive MRI Native T1 Mapping Detects Response to MYCN -targeted Therapies in the Th- MYCN Model of Neuroblastoma Cancer Research ·Konstantinos Zormpas‐Petridis, Evon Poon, Matthew Clarke, Neil P. Jerome, Jessica K.R. Boult, Matthew Blackledge, Fernando Carceller, Alexander Koers, Giuseppe Barone, Andrew D.J. Pearson, Lucas Moreno, John Anderson, Neil J. Sebire, Kieran McHugh, Dow‐Mu Koh, Louis Chesler, Yinyin Yuan, Simon P. Robinson, Yann Jamin	2020	21
3	Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736 Blood Advances ·Andrew S. Moore, Amir Faisal, Grace Wing-Yan Mak, Farideh Miraki‐Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D.J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David Taussig, Spiros Linardopoulos	2020	20
4	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project Pediatric Blood & Cancer ·V. V. Moroz, David Machin, Barbara Hero, Ruth Ladenstein, Frank Berthold, Paige Kao, Yaa Obeng, Andrew D.J. Pearson, Susan L. Cohn, Wendy B. London	2020	32
5	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors Clinical Cancer Research ·Mark W. Kieran, Birgit Geoerger, Ira J. Dunkel, Alberto Broniscer, Darren Hargrave, Pooja Hingorani, Isabelle Aerts, Anne-Isabelle Bertozzi, Kenneth J. Cohen, Trent R. Hummel, Violet Shen, Éric Bouffet, Christine A. Pratilas, Andrew D.J. Pearson, Lillian Tseng, Noelia Nebot, Steven Green, Mark W. Russo, James A. Whitlock	2019	58
6	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors Clinical Cancer Research ·Birgit Geoerger, Franck Bourdeaut, Steven G. DuBois, Matthias Fischer, James I. Geller, Nicholas G. Gottardo, Aurélien Marabelle, Andrew D.J. Pearson, Shakeel Modak, Thomas F. Cash, Giles Robinson, Marlyane Motta, Alessandro Matano, Suraj G. Bhansali, Jason R. Dobson, Sudha Parasuraman, Susan Chi	2017	121
7	A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study Clinical Cancer Research ·Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell‐Hewson, Guy Makin, Sarah Halford, Gary D Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Isabel Enríquez Rodríguez, John F. Lyons, Alan V. Boddy, Melanie J. Griffin, Murray Yule, Darren Hargrave	2014	39
8	MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance Current Drug Targets ·Giuseppe Barone, Deborah A. Tweddle, Jason M. Shohet, Louis Chesler, Lucas Moreno, Andrew D.J. Pearson, Tom Van Maerken	2014	33
9	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo Clinical Cancer Research ·Jane Renshaw, Kathryn R. Taylor, Ryan T. Bishop, Melanie Valenti, Alexis de Haven Brandon, Sharon Gowan, Suzanne A. Eccles, Ruth Ruddle, Louise D. Johnson, Florence I. Raynaud, Joanna Selfe, Khin Thway, Torsten Pietsch, Andrew D.J. Pearson, Janet Shipley	2013	110
10	Adaptive Dosing Approaches to the Individualization of 13- Cis -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma Clinical Cancer Research ·Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, Ghada Malik, Michael Cole, Ann K. Daly, Andrew D.J. Pearson, Alan V. Boddy	2012	38
11	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age Journal of Clinical Oncology ·Denah R. Taggart, Wendy B. London, Mary Lou Schmidt, Steven G. DuBois, Tom Monclair, Akira Nakagawara, Bruno De Bernardi, Peter F. Ambros, Andrew D.J. Pearson, Susan L. Cohn, Katherine K. Matthay	2011	48
12	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project Journal of Clinical Oncology ·Wendy B. London, Victoria Castel, Tom Monclair, Peter F. Ambros, Andrew D.J. Pearson, Susan L. Cohn, Frank Berthold, Akira Nakagawara, Ruth Ladenstein, Tomoko Iehara, Katherine K. Matthay	2011	229
13	Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma Molecular Cancer Therapeutics ·Nathalie Gaspar, Swee Y. Sharp, Suzanne A. Eccles, Sharon Gowan, Sergey Popov, Chris Jones, Andrew D.J. Pearson, Gilles Vassal, Paul Workman	2010	62
14	Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells Cancer Research ·Nathalie Gaspar, Swee Y. Sharp, Simon Pacey, Chris Jones, Michael I. Walton, Gilles Vassal, Suzanne A. Eccles, Andrew D.J. Pearson, Paul Workman	2009	92
15	EGFRvIII Deletion Mutations in Pediatric High-Grade Glioma and Response to Targeted Therapy in Pediatric Glioma Cell Lines Clinical Cancer Research ·Dorine A. Bax, Nathalie Gaspar, Suzanne E. Little, Lynley V. Marshall, Lara Perryman, Marie Regairaz, Marta Viana‐Pereira, Raisa Vuononvirta, Swee Y. Sharp, Jorge S. Reis‐Filho, João N. Stávale, Safa Al‐Sarraj, Rui Manuel Reis, Gilles Vassal, Andrew D.J. Pearson, Darren Hargrave, David W. Ellison, Paul Workman, Chris Jones	2009	71
16	Acquired resistance to HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines Cancer Research ·Nathalie Gaspar, Swee Y. Sharp, Simon Pacey, Chris Jones, Mike Walton, Gilles Vassal, Andrew D.J. Pearson, Paul Workman	2008	1
17	β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee Journal of Clinical Oncology ·David W. Ellison, Olabisi E. Onilude, Janet C. Lindsey, Meryl E. Lusher, Claire Weston, Roger Taylor, Andrew D.J. Pearson, Steven C. Clifford	2005	290
18	Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer British Journal of Cancer ·Iain Willits, L Price, A Parry, Michael J. Tilby, Dianne Ford, S. Cholerton, Andrew D.J. Pearson, Alan V. Boddy	2005	11
19	Temozolomide in malignant gliomas of childhood Journal of Clinical Oncology ·L. S. Lashford, Philippe Thiesse, Anne Jouvet, T. Jaspan, D. Couanet, P. D. Griffiths, François Doz, James W. Ironside, K. Robson, Rachel Hobson, Margaret Dugan, Andrew D.J. Pearson, Gilles Vassal, Didier Frappaz	2002	2
20	Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration Cancer Chemotherapy and Pharmacology ·Alan V. Boddy, S. Murray Yule, Ruth Wyllie, L Price, Andrew D.J. Pearson, Jeffrey R. Idle	1996	27

About Andrew D.J. Pearson

Andrew D.J. Pearson is a scholar working on Neurology, Cancer Research, Genetics, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health, having authored 224 papers that have together received 11.4k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (109 papers), Cancer, Hypoxia, and Metabolism (49 papers), Cancer therapeutics and mechanisms (43 papers), Chemotherapy-induced organ toxicity mitigation (25 papers), Childhood Cancer Survivors' Quality of Life (25 papers), Neuroendocrine Tumor Research Advances (24 papers), Acute Lymphoblastic Leukemia research (21 papers) and Glioma Diagnosis and Treatment (21 papers). The work is most often cited by research in Neurology (6.9k citations), Cancer Research (3.1k citations), Genetics (1.5k citations), Oncology (2.3k citations) and Molecular Biology (5.4k citations). Andrew D.J. Pearson has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Susan L. Cohn, Katherine K. Matthay, Wendy B. London, Peter F. Ambros, Tom Monclair, David Machin, Thorsten Simon, Alan V. Boddy, L Price and Garrett M. Brodeur. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Pediatric Blood & Cancer, British Journal of Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact